Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 100,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $89.48, for a total value of $8,948,000.00. Following the completion of the transaction, the director owned 501,477 shares of the company’s stock, valued at approximately $44,872,161.96. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Liquidia Stock Up 2.8%

NASDAQ:LQDA opened at $86.82 on Wednesday. Liquidia Corporation has a twelve month low of $16.82 and a twelve month high of $91.10. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of 620.19 and a beta of 0.55. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock’s 50 day moving average price is $72.31 and its two-hundred day moving average price is $50.98.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue was up 4187.1% on a year-over-year basis. Equities research analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: LifeSci Capital maintained its Buy rating on Liquidia, supporting the bullish view of the company’s outlook. LifeSci Capital Sticks to Their Buy Rating for Liquidia
• Positive Sentiment: HC Wainwright expressed a positive view of Liquidia’s fiscal 2027 earnings prospects, suggesting analysts expect meaningful future growth. HC Wainwright Has Positive View of Liquidia FY2027 Earnings
• Positive Sentiment: Buckley Capital Advisors said Liquidia could have more than 50% upside, citing the upcoming YUTREPIA ruling and potential buyout interest. This reinforces the importance of regulatory and strategic catalysts for LQDA. Liquidia Has 50% Plus Upside on YUTREPIA Ruling and Buyout Potential
• Neutral Sentiment: Recent valuation coverage highlights a debate between YUTREPIA-driven growth and patent risk. Another analysis argues the stock still looks expensive as YUTREPIA expansion progresses, indicating that further appreciation depends on execution and successful intellectual-property outcomes. Liquidia Rallies as Fair Value Debate Turns on Growth and Patent Risk Liquidia Stock Still Looks Expensive
• Negative Sentiment: Director Stephen M. Bloch disclosed three sales totaling 178,596 shares for approximately $15.2 million between July 20 and July 23. Although he retained a substantial position, the sizable reduction could weigh on sentiment because it signals insider profit-taking after LQDA’s strong run. SEC Insider Transaction Filing

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LQDA. BTIG Research lifted their price objective on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Needham & Company LLC raised their target price on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Bank of America reiterated a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research report on Friday. Finally, Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $86.18.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB bought a new position in shares of Liquidia in the second quarter valued at about $1,993,000. Fulcrum Equity Management acquired a new position in Liquidia in the 2nd quarter valued at about $399,000. Fluent Financial LLC bought a new position in Liquidia in the 2nd quarter valued at about $287,000. FNY Investment Advisers LLC bought a new position in Liquidia in the 2nd quarter valued at about $1,395,000. Finally, Seven Fleet Capital Management LP lifted its position in Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after acquiring an additional 113,609 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).